SAN DIEGO—(BUSINESS WIRE)—Sep. 3, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that its Board of Directors has appointed Steve Davis as
President and Chief Executive Officer. Mr. Davis has been serving as
ACADIA’s Interim Chief Executive Officer since March 2015. Mr. Davis has
also been appointed to the ACADIA Board of Directors.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150903005511/en/
Steve Davis, Chief Executive Officer of ACADIA Pharmaceuticals (Photo: Business Wire)
“We are delighted that Steve is our Chief Executive Officer,” said
Leslie L. Iversen, Ph.D., ACADIA’s Chairman of the Board. “He is an
accomplished leader and since joining ACADIA, Steve has done a
tremendous job of aligning ACADIA’s operations with our short-term and
long-term goals, continuing the build-out of our capabilities, and
positioning the Company for strong growth. I have great confidence in
Steve leading ACADIA through our next stage of growth as we bring
innovative treatments such as NUPLAZID™ to CNS disease states
with high unmet medical needs.”
“With Breakthrough Therapy designation and our submission of the New
Drug Application for NUPLAZID for Parkinson’s disease psychosis, we have
an opportunity to transform the treatment of psychosis and significantly
improve the lives of these patients,” said Steve Davis, ACADIA’s Chief
Executive Officer. “We are building on our momentum as we prepare for
the expected launch of NUPLAZID in the United States and continue our
efforts to explore the full potential of NUPLAZID to treat patients
suffering from additional CNS disorders.”
Mr. Davis brings over 20 years of executive-level experience in the
pharmaceutical industry and more than 20 years of experience on the
boards of directors of publicly held biopharmaceutical companies. He
joined ACADIA in July 2014 as Executive Vice President, Chief Financial
Officer and Chief Business Officer and was appointed Interim Chief
Executive Officer in March 2015. Previously, Mr. Davis served as
Executive Vice President and Chief Operating Officer at Heron
Therapeutics, Inc., Executive Vice President and Chief Operating Officer
at Ardea Biosciences, Inc., and in numerous executive roles at Neurogen
Corporation, including Chief Executive Officer. Mr. Davis currently
serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. He
also recently served on the boards of directors of Synageva BioPharma
Corp., Heron Therapeutics, and Furiex Pharmaceuticals, Inc.
Early in his career, Mr. Davis practiced as a Certified Public
Accountant with a major accounting firm and as a corporate and
securities attorney with a Wall Street law firm. Mr. Davis received his
Bachelor of Science degree in Accounting from Southern Nazarene
University and a J.D. from Vanderbilt University.
Separately, ACADIA issued a news release today announcing that it has
submitted a New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) seeking approval for NUPLAZID (pimavanserin)
for the treatment of psychosis associated with Parkinson’s disease.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has a pipeline of product
candidates led by NUPLAZID™ (pimavanserin), for which we have submitted
a New Drug Application in Parkinson’s disease psychosis to the FDA and
which has the potential to be the first drug approved in the United
States for this condition. Pimavanserin is also in Phase II development
for Alzheimer’s disease psychosis and has successfully completed a Phase
II trial in schizophrenia. ACADIA also has clinical-stage programs for
chronic pain and glaucoma in collaboration with Allergan, Inc. All
product candidates are small molecules that emanate from internal
discoveries. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to ACADIA’s positioning for strong
growth; ACADIA’s ability to bring innovative treatments such as NUPLAZID
to CNS disease states with high unmet medical needs; the potential for
NUPLAZID (pimavanserin) to be the first drug approved in the United
States for Parkinson’s disease psychosis (PDP), if approved at all, and
the expected launch of NUPLAZID for PDP; ACADIA’s opportunity to
transform the treatment of psychosis and significantly improve the lives
of patients with PDP with NUPLAZID; the potential of NUPLAZID to treat
patients suffering from CNS disorders other than PDP; and the progress,
timing and results of ACADIA’s drug discovery and development programs,
either alone or with a partner, including the progress and expected
timing of clinical trials. These statements are only predictions based
on current information and expectations and involve a number of risks
and uncertainties. Actual events or results may differ materially from
those projected in any of such statements due to various factors,
including the risks and uncertainties inherent in drug discovery,
development, approval and commercialization, and in collaborations with
others, and the fact that past results of clinical trials may not be
indicative of future trial results. For a discussion of these and other
factors, please refer to ACADIA’s annual report on Form 10-K for the
year ended December 31, 2014 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903005511/en/
Source: ACADIA Pharmaceuticals Inc.
Investor Contacts:
ACADIA Pharmaceuticals Inc.
Steve
Davis, Chief Executive Officer
Lisa Barthelemy, Director of
Investor Relations
(858) 558-2871
or
Media
Contact:
Russo Partners
David Schull
(212)
845-4271 or (858) 717-2310
[email protected]